OLR1 and colorectal adenocarcinoma: As a further proof of concept of the molecular foundation of our method, we used Principal Component Analysis (PCA)54 to investigate the mutual relationship between the four colorectal adenocarcinoma cell classes (DLD-1 scramble, LOX-1 inhibited and treated at 125 and 250 μg/ml), with particular attention to the relation between the LOX-1 inhibited class (DLD-1 #5) and the class treated with Bevacizumab at intermediate concentration (125 μg/mL).